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Cancer stem cellsAbstract The molecular mechanisms of tumor metastasis remain largely unknown and undeﬁned.
A recent model suggests that a minor population of cells (cancer stem cells) is programmed to
preferentially metastasize to speciﬁc organs based on their gene expression patterns. These cells
have the ability to generate tumors after implantation into animal hosts, to self-renew and give rise
to non-stem cells. In this paper I hypothesize that epigenetic mechanisms could play an important
role in tumor metastasis through the reorganization of the bivalent chromatin marks in cancer stem
cells in three phases: 1) the reprogramming of epigenetic marks in differentiation master regulator
genes responsible for the differentiation to one particular lineage 2) the resolution of these bivalent
chromatin marks forces cells to develop the necessary mechanisms to migrate to a new niche and 3)
the epigenetic activation of the tissue-speciﬁc genes associated with the speciﬁc target organ and,
simultaneously, the repression of genes associated with alternative developmental pathways.
ª 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Epigenetics is the study of mechanisms that control gene
expression in a potentially heritable way [1]. In humans,
histone modiﬁcation represents one prominent form of
chromatin remodeling, which results in dynamic and revers-
ible post-translational modiﬁcations of the residues at theN-terminal tails of histones. These modiﬁcations are mediated
by sets of enzymatic complexes that site-speciﬁcally attach or
remove chemical groups [2].
The histone modiﬁcations described so far include acetyla-
tion, methylation, phosphorylation, ubiquitination, SUMO-
ylation, and ADP-ribosylation. This epigenetic mechanism
has a central role in processes such as DNA repair, DNA6, 28871
The progression of cancer and metastasis formation: An epigenetic hypothesis 21replication, alternative splicing, and chromosome condensa-
tion. In regards to gene regulation, histone modiﬁcations are
associated with both transcriptional repression and activation.
In general, acetylation and deacetylation of the e-amino
groups of conserved lysine residues present in histone tails
by histone acetylases and deacetylases, respectively, has long
been linked to a more relaxed chromatin state, which is condu-
cive to gene expression [3], also playing important roles in the
regulation of DNA replication and DNA repair [4]. Methyla-
tion by histone methyltransferases correlates with transcrip-
tional activation and repression. Thus, we associate
euchromatin with high levels of acetylation and trimethylated
H3K4, H3K36, and H3K79, while heterochromatin, on the
contrary, is associated with limited acetylation marks and high
levels of H3K9, H3K27, and H4K20 methylation.
These mechanisms play a role in the maintenance and dif-
ferentiation of embryonic stem cells (ES cells) thought poly-
comb groups that establish epigenetic control of important
regulator genes that regulate future expression patterns [5].
In these cells, we observed a bivalent chromatin structure in
which active and repressive chromatin marks are closely juxta-
posed mainly in genes with promoters enriched in CpG islands
that correspond with important tissue-speciﬁc regulator genes
[6]. It is during differentiation that bivalent chromatin proﬁles
are generally resolved, leading to transcriptional activation of
tissue-speciﬁc genes and the silencing of loci associated with
alternative developmental pathways [5]. In summary, ES cells
have the potential to differentiate into any cell type in the
body, and this potential is related to speciﬁc histone modiﬁca-
tions [7]. This process has been described in normal ES cells,
but the role of the bivalent chromatin structure in the patho-
physiology of different diseases, speciﬁcally in cancer, has yet
to be elucidated.
Tumors contain multiple types of cells, some of which con-
tribute to different processes, such as metastasis. This is a com-
plex, multi-step process that represents the spread of cancer
cells from the primary tumor sites to distant organs and
tissues. In spite of its clinical importance, the molecular
mechanisms driving metastasis remain unknown. However,
certain cancers have distinct organ colonization patterns. For
example, colon cancer usually metastasizes to the liver, while
liver cancer and rectal carcinoma disseminate predominantly
to the lungs [8]. This topology of metastasis formation is
based, from a genetic perspective, on the existence of metasta-
sis gene signatures expressed by the primary tumors [8,9]. For
example, genes such as COX2, ST6GALNAC5, and EGFR
ligands mediate breast cancer metastasis to the brain [10],
and the MMP1, VCAM1, and GRO1/CXCL1 genes mediate
breast cancer metastasis to the lung [9]. These speciﬁc
processes are carried out by a minor population of cells, cancer
stem cells (CSCs), which are programmed to preferentially
metastasize to speciﬁc organs based on their gene expression
patterns [11]. These cells have the ability to generate tumors
after implantation into animal hosts, and to self-renew and give
rise to non-stem cells [12], showing a dynamic equilibrium
between CSCs and non-CSCs that could be shifted in one direc-
tion or another by contextual signals within the tumor microen-
vironment [13]. It is important to highlight that, while CSCs
can differentiate into non-CSCs, the reverse process must also
be considered [13]. In the last years, a CSC-based model for
metastasis has been proposed and suggests that CSCs inherit
a unique set of genetic and/or epigenetic changes thatdetermine the cancer malignancy, metastatic potential, and
the tissue tropism that is regulated by cues such as oxygen gra-
dients or other chemo-attractants derived from niche sites [11].
Compelling data indicate that CSCs could have a central
role in metastasis, and an improved understanding of this role
may lead to novel therapeutic strategies against cancer. There-
fore, I hypothesize that the reorganization of the bivalent chro-
matin marks in a subpopulation of cells within a tumor leads
to a differentiation of non-CSCs to CSCs, the latter being
responsible for the metastatic process.
The hypothesis
As previously stated, the presence of bivalent chromatin struc-
ture at tissue-speciﬁc regulator genes plays an important role
in the maintenance and differentiation of ES cells. Therefore,
the differentiation of ES cells to one particular lineage is an
epigenetic phenomenon characterized by the presence of a
speciﬁc chromatin structure that implies the permanent and
irreversible silencing of genes involved in alternative lineages
(Fig. 1).
While this epigenetic signature has been described in ES
cells, the role of this bivalent chromatin structure in the meta-
static process is unknown. As previously mentioned, within a
tumor, non-CSCs can be reprogrammed into CSCs given cer-
tain contextual signals. I suggest that this transdifferentiation
is structured in three phases: First, the transition from non-
CSCs to CSCs could be mediated by the reprogramming of epi-
genetic marks in differentiation master regulator genes respon-
sible for the differentiation to one particular lineage, such that
the new CSCs have properties similar to ES cells. Second, this
bivalent chromatin signature will be resolved with a pattern
of absence of DNA methylation and H3K4me3 in speciﬁc cell
lineage genes and, simultaneously, a presence of repressive
marks (i.e. H3K9me3, H3K27me3, and DNA methylation) in
genes involved in the rest of alternative cell lineages; this pat-
tern stimulates differentiation into a speciﬁc cell lineage and
give a new identity to the CSC. This, in turn, forces cells to
develop the necessary mechanisms to migrate to a new niche
(i.e. the epithelial–mesenchymal transition or EMT) and,
ﬁnally, when the CSCs arrive at the new organ, in order to
activate the tissue-speciﬁc genes associated with this organ,
they simultaneously gain H3K4me3 and lose DNAmethylation
while others, which represent genes associated with alternative
developmental pathways, show epigenetic repressive marks,
such as H3K9me3, H3K27me3, and DNA methylation.Evaluation of the hypothesis
I will focus on one type of cancer, for example, colon cancer
that, as I have already pointed, usually metastasizes to the
liver. Although in vitro cell culture models will be useful in
understanding the origins of CSCs (transition from non-CSCs
to CSCs) and when and where they arise during cancer initia-
tion and progression, we can use mouse cancer models in order
to obtain, ﬁrst, colon non-CSCs and, second, obtain CSCs
after the repeated intraperitoneal administration of the
mutagenic agent azoxymethane (AOM) that results in the
development of spontaneous tumors [14]. The chromatin anal-
ysis could be done through Chromatin immunoprecipitation
(ChIP), which is routinely used to examine epigenetic
Fig. 1 Bivalent chromatin marks in ES cells and during differentiation to muscle cells.
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hypothesis is right, we will have three different chromatin
signatures associated with different cell populations: a tempo-
ral bivalent epigenetic one (CSCs), a temporal differentiation
signature (new liver-CSCs) and a stable tissue-speciﬁc signa-
ture (colon non-CSCs). Temporal differentiation signature will
be also characterized by the expression of FOXA3, HNF1A,
and HNF4A, genes that regulate hepatic genes programs
and, therefore, related with functions characteristic of hepato-
cytes [15]. To analyze the different gene expression signatures
associated with each type of cells, we will employ the csSAM,
a methodology that enables the analysis of gene expression in
complex tissues at a much higher resolution than previously
possible [16]. Finally, we have to explore the liver cell popula-
tion in order to analyze the activation of the tissue-speciﬁc
genes associated with this organ.Consequences of the hypothesis and discussion
To date, epigenetic mechanisms have been described that play
a key role in different processes, both in healthy and disease
states, for example silencing or activating speciﬁc genes in can-
cer or resolving bivalent chromatin proﬁles in ES cells. But epi-
genetic mechanisms could provide a link between these two
processes, apparently disconnected; that is, what is the role
of this bivalent chromatin structure in the metastatic process?
We know that CSCs are considered to be the root of cancer
and could be responsible for cancer metastasis, but its molec-
ular mechanisms remain largely unknown and undeﬁned. In
the present paper I hypothesize that epigenetic mechanisms
could play an important role in cancer progression through
the reorganization of the bivalent chromatin marks in these
CSCs. This process is structured in three hits, in consonance
with the well-accepted Knudson hypothesis. The ﬁrst hit
involves the erasing of epigenetic marks in differentiation mas-
ter regulator genes. This event is following with the second hit:
the reorganization of histone marks, that results in a newtemporal cell identity, which forces cells to develop migration
mechanisms. Finally, the third hit involves the epigenetic acti-
vation of the tissue-speciﬁc genes associated with the speciﬁc
target organ and, simultaneously, the repression of genes asso-
ciated with alternative developmental pathways. In summary, I
think that the identiﬁcation of the epigenetic reprogramming
events in non-CSCs proposed in this paper could have pro-
found implications for cancer therapies targeting CSCs.Overview box
First Question: What do we already know about the
subject?
Cancer represents one of the most lethal pathologies
affecting mankind. Although its molecular mechanisms
remain largely unknown and undeﬁned, recent studies
suggests that CSCs are involved in the metastasis process
to speciﬁc organs based on their gene expression patterns.
Second Question: What does your proposed theory
add to the current knowledge available, and what beneﬁts
does it have?
Although many studies focus on the genetic signatures
that distinguish CSCs from normal tissue stem cells, none
has described the epigenetic regulation of this cell popula-
tion. If the hypothesis is right, we could understand the
molecular mechanisms driving metastasis and, therefore,
develop new therapeutic strategies based on epigenetic
approaches (i.e. by developing new histone deacetylase
inhibitors, as EPZ005687, targeting the key enzymes reg-
ulating EMT or cancer progression).
Third Question: Among numerous available studies,
what special further study is proposed for testing the idea?
In order to evaluate the idea, animal models should be
conducted. If we obtain positive results, a detailed study
including human cancer samples would be necessary in
order to validate or refuse the hypothesis.
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